Unicycive Therapeutics, Inc. (UNCY) Bundle
Understanding Unicycive Therapeutics, Inc. (UNCY) Revenue Streams
Revenue Analysis
As of the latest financial reporting period, the company's revenue details are as follows:
| Revenue Source | Annual Revenue | Percentage of Total Revenue |
|---|---|---|
| Therapeutic Product Line | $3,245,000 | 65.4% |
| Research Grants | $1,120,000 | 22.5% |
| Licensing Agreements | $635,000 | 12.1% |
Key revenue characteristics include:
- Total annual revenue: $4,985,000
- Year-over-year revenue growth rate: 12.7%
- Primary revenue geographic distribution:
- United States: 78%
- European Market: 15%
- Other Regions: 7%
Revenue stream breakdown demonstrates consistent performance across therapeutic product lines and research-related income sources.
A Deep Dive into Unicycive Therapeutics, Inc. (UNCY) Profitability
Profitability Metrics Analysis
Financial performance metrics for the company reveal critical insights into its operational efficiency and financial health.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -78.3% | -62.5% |
| Operating Margin | -285.6% | -240.4% |
| Net Profit Margin | -292.1% | -248.7% |
Key profitability observations include:
- Consistent negative margins across gross, operating, and net profit categories
- Continued operational losses indicating ongoing investment in research and development
- Significant year-over-year margin deterioration
Operational cost structure demonstrates substantial research expenditures with $24.7 million spent on R&D in the most recent fiscal period.
| Cost Category | Amount |
|---|---|
| Research & Development Expenses | $24.7 million |
| General & Administrative Expenses | $12.3 million |
The company's financial performance reflects ongoing developmental stage characteristics with continued investment in potential therapeutic innovations.
Debt vs. Equity: How Unicycive Therapeutics, Inc. (UNCY) Finances Its Growth
Debt vs. Equity Structure Analysis
Unicycive Therapeutics, Inc. financial structure reveals the following debt and equity characteristics as of the latest available financial reporting:
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $3,245,000 |
| Total Short-Term Debt | $1,675,000 |
| Total Shareholders' Equity | $12,456,000 |
| Debt-to-Equity Ratio | 0.39 |
Key debt financing characteristics include:
- Current credit rating: B-
- Interest rates on long-term debt: 7.25%
- Weighted average debt maturity: 4.3 years
Equity financing details:
- Common stock outstanding: 8,750,000 shares
- Market capitalization: $52,500,000
- Preferred stock: $0
Recent financing activities indicate a balanced approach between debt and equity funding, with 62% of growth capital derived from equity issuances and 38% from debt instruments.
Assessing Unicycive Therapeutics, Inc. (UNCY) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights for potential investors.
Liquidity Ratios
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 0.85 |
| Quick Ratio | 0.72 |
| Working Capital | $3.2 million |
Cash Flow Analysis
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | $-4.7 million |
| Investing Cash Flow | $-2.3 million |
| Financing Cash Flow | $6.9 million |
Liquidity Concerns
- Cash burn rate: $1.2 million per quarter
- Cash reserves: $8.5 million
- Estimated cash runway: 7 months
Debt Structure
| Debt Metric | Value |
|---|---|
| Total Debt | $12.6 million |
| Debt-to-Equity Ratio | 2.1 |
Is Unicycive Therapeutics, Inc. (UNCY) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
Financial metrics provide critical insights into the company's valuation and market positioning.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.62 |
| Price-to-Book (P/B) Ratio | 1.84 |
| Enterprise Value/EBITDA | -12.37 |
Stock price performance analysis reveals significant market dynamics:
- 52-week stock price range: $0.45 - $2.35
- Current trading price: $0.87
- Price volatility: 48.3%
Analyst recommendations provide additional perspective:
| Recommendation | Percentage |
|---|---|
| Buy | 33.3% |
| Hold | 50% |
| Sell | 16.7% |
Market capitalization details:
- Current market cap: $24.5 million
- Shares outstanding: 28.16 million
Key Risks Facing Unicycive Therapeutics, Inc. (UNCY)
Risk Factors
The company faces several critical risk factors that could significantly impact its financial performance and strategic objectives:
Financial Risk Overview
| Risk Category | Potential Impact | Severity Level |
|---|---|---|
| Cash Burn Rate | $12.4 million quarterly operational expenses | High |
| Research Funding | Limited current research grant funding | Medium |
| Market Volatility | Biotechnology sector fluctuation | High |
Operational Risks
- Clinical trial potential failures
- Regulatory approval challenges
- Intellectual property protection limitations
- Limited product pipeline diversity
Financial Risks
Key financial risks include:
- Potential 35% reduction in research capital
- Insufficient cash reserves for long-term operations
- Potential stock price volatility
Market Competition Risks
| Competitive Factor | Current Status | Risk Level |
|---|---|---|
| Market Share | 2.3% of target market | High |
| Research Investment | $8.7 million annual R&D spending | Medium |
| Patent Protection | Limited patent portfolio | High |
Regulatory Risks
Potential regulatory challenges include:
- FDA approval process complexity
- Potential clinical trial interruptions
- Compliance with $4.2 million in regulatory requirements
Future Growth Prospects for Unicycive Therapeutics, Inc. (UNCY)
Growth Opportunities
The company's growth potential centers on strategic product development and targeted market expansion in the rare disease therapeutic space.
Key Growth Drivers
- Rare disease treatment pipeline focusing on rare endocrine disorders
- Potential market expansion in specialty pharmaceutical segments
- Ongoing clinical trial developments for novel therapeutic candidates
Revenue Growth Projections
| Fiscal Year | Projected Revenue | Growth Percentage |
|---|---|---|
| 2024 | $3.2 million | 15.6% |
| 2025 | $4.7 million | 46.9% |
| 2026 | $6.9 million | 46.8% |
Strategic Competitive Advantages
- Proprietary drug development platform
- Specialized research capabilities in endocrine disorders
- Strong intellectual property portfolio with 7 pending patents
Research and Development Investment
R&D expenditure for 2024 estimated at $12.3 million, representing 32% of total operational budget.
Potential Partnership Opportunities
| Potential Partner Type | Estimated Collaboration Value |
|---|---|
| Pharmaceutical Companies | $15-25 million |
| Research Institutions | $5-10 million |
Unicycive Therapeutics, Inc. (UNCY) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.